<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00241098</url>
  </required_header>
  <id_info>
    <org_study_id>CVAL489B2402</org_study_id>
    <nct_id>NCT00241098</nct_id>
  </id_info>
  <brief_title>The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure</brief_title>
  <official_title>A Randomized, Double Blind, Parallel Group Study to Evaluate the Effects of Valsartan Versus Placebo in Patients With Early Stage Heart Failure Due to Diastolic Dysfunction Already Evidenced by an Elevated B-type Natriuretic Peptide Level: the VALIDATE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a study to evaluate the response of patients with hypertension and early stage heart
      failure to valsartan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in a blood measurement for heart failure after 26 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in a blood measurement for heart failure after 12 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline heart size after 26 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline heart size, heart function, and other parameters of diastolic heart dysfunction after 26 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in markers of heart fibrosis after 26 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline quality of life questionnaire after 26 weeks</measure>
  </secondary_outcome>
  <enrollment type="Actual">37</enrollment>
  <condition>Hypertension</condition>
  <condition>Congestive Heart Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 25-85 years of age, inclusive

          -  Past diagnosis of hypertension for a min 1 year

          -  Patients with an established treatment regimen for hypertension with one or more
             agents for a minimum period of 2 months

          -  BP is considered adequately controlled with DBP &lt; 90mmHg

          -  Elevated BNP levels both in bedside test (62pg/ml) and after validation of a separate
             blood sample (40pg/ml) in the central laboratory

          -  LV ejection fraction ³ 45%

          -  LVH defined as myocardial mass ³ 116 g /m2 in males and 104 g/m2 in females

          -  At least one of the following parameters of diastolic dysfunction

               -  E/A &lt; 1 for the patients who are younger than 55 years or &lt; 0.8 for the patients
                  whose age is ³ 55 years (full year), or

               -  DT &gt; 220 ms, or

               -  IVRT &gt; 90 ms

        Exclusion Criteria:

        • Present use of ACE inhibitor

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceutical</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>February 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2005</study_first_submitted>
  <study_first_submitted_qc>October 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2005</study_first_posted>
  <last_update_submitted>November 7, 2011</last_update_submitted>
  <last_update_submitted_qc>November 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HYPERTENSION</keyword>
  <keyword>HEART FAILURE</keyword>
  <keyword>PEPTIDE</keyword>
  <keyword>valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

